We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PerkinElmer Collaborates on Preterm Birth Biomarkers

By HospiMedica staff writers
Posted on 21 Aug 2006
PerkinElmer, Inc. More...
(Wellesley, MA, USA) has announced a multi-year license-and-research agreement with the University of Leicester (Leicester, United Kingdom) under which the two organizations will begin to lay the groundwork for the clinical investigation and discovery of biomarkers that predict preterm birth (PTB). The collaboration will be financed by PerkinElmer.

PerkinElmer will support the expansion of the University of Leicester's maternal health research capabilities and provide advanced tools, technology, and expertise. Professor J. C. Konje, M.D., and colleagues of Leicester University's reproductive sciences section of the department of cancer studies and molecular medicine are dedicated to the study and prediction of preterm birth. The team is conducting research in the field of preterm labor diagnosis.

The partnership will give PerkinElmer broader access within Professor Konje's research group to clinical samples, methodology, and clinical consultancy support in the field of maternal health. The University of Leicester and PerkinElmer will work towards validating any new PTB biomarkers that will complement PerkinElmer's maternal health portfolio. PerkinElmer and the University of Leicester will share access to licensed intellectual property from new PTB biomarkers that result from this research.

It is estimated that preterm labor complicates 6-10% of all pregnancies and is the most common cause of neonatal morbidity and mortality. Worldwide statistics reflect that there may be as many as 13 million preterm births annually, and this figure is predicted to increase. In the United States alone, an estimated U.S.$820 million is spent on preterm hospitalization subsequently shown to have been unnecessary. These hospitalizations tax both the mother's health and healthcare resources.

Currently, there are no rapid or accurate tests that positively predict preterm labor. The aim of the collaboration between PerkinElmer and the University of Leicester is to effectively address this need and eventually design and supply an effective preterm labor test predictor.



Related Links:
PerkinElmer
University of Leicester

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
HPV Test
Allplex HPV28 Detection
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.